Evidence map›Paper›PMID 36863493›Full record

ArticleBrain, behavior, and immunity2023

Chronic ethanol induces a pro-inflammatory switch in interleukin-1β regulation of GABAergic signaling in the medial prefrontal cortex of male mice.

F P Varodayan, A R Pahng, T D Davis, P Gandhi, M Bajo, M Q Steinman, W B Kiosses, Y A Blednov, M D Burkart, S Edwards and 2 more

Abstract read
In one paragraph

Article in Brain, behavior, and immunity, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed.

  1. Article
  2. Major depressive disorder-alcohol use disorder comorbidity: diagnosis, mechanisms and treatment.European archives of psychiatry and clinical neuroscience · 2026
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Astrocyte Reactivity by Alcohol Dependence in the Central Amygdala.bioRxiv : the preprint server for biology · 2026
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Novel neurotherapeutic targets for substance use disorders: Neuroplasticity, neuroinflammation, gasotransmitters and non-canonical organ systems.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

F P VarodayanDepartment of Molecular Medicine, The Scripps Research Institute, La Jolla, CA, USA; Developmental Exposure Alcohol Research Center and Behavioral Neuroscience Program, Department of Psychology, Binghamton University-SUNY, Binghamton, NY, USA.
A R PahngDepartment of Physiology, Louisiana State University Health Sciences Center, New Orleans, LA, USA; Southeast Louisiana Veterans Health Care System, New Orleans, LA, USA.
T D DavisDepartment of Chemistry & Biochemistry, University of California, San Diego, La Jolla, CA, USA; Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, Binghamton University-SUNY, Binghamton, NY, USA.
P GandhiDepartment of Molecular Medicine, The Scripps Research Institute, La Jolla, CA, USA.
M BajoDepartment of Molecular Medicine, The Scripps Research Institute, La Jolla, CA, USA.
M Q SteinmanDepartment of Molecular Medicine, The Scripps Research Institute, La Jolla, CA, USA.
W B KiossesMicroscopy Core Imaging Facility, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
Y A BlednovWaggoner Center for Alcohol and Addiction Research, University of Texas at Austin, Austin, TX 78712, USA.
M D BurkartDepartment of Chemistry & Biochemistry, University of California, San Diego, La Jolla, CA, USA.
S EdwardsDepartment of Physiology, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
A J RobertsAnimal Models Core Facility, The Scripps Research Institute, La Jolla, CA, USA.
M RobertoDepartment of Molecular Medicine, The Scripps Research Institute, La Jolla, CA, USA. Electronic address: mroberto@scripps.edu.

Funding

Viral Vector CoreP60AA006420 · NIAAA · SCRIPPS RESEARCH INSTITUTE, THE · PI AMANDA J ROBERTS · 2003 to 2026
$46.3M
Social Anxiety, Stress and Ethanol Sensitivity in Adolescence and AdulthoodP50AA017823 · NIAAA · UPSTATE MEDICAL UNIVERSITY · PI J. DAVID JENTSCH · 2009 to 2026
$30.5M
Neurpsychopharmacology-Multidisciplinary TrainingT32AA007456 · NIAAA · SCRIPPS RESEARCH INSTITUTE, THE · PI MARISA ROBERTO · 1985 to 2026
$13.4M
Electrophysiology of alcohol in extended amygdelaU01AA013498 · NIAAA · SCRIPPS RESEARCH INSTITUTE, THE · PI MARISA ROBERTO · 2001 to 2026
$12.6M
INIA: ANIMAL COREU01AA013520 · NIAAA · UNIVERSITY OF TEXAS AUSTIN · PI YURI A BLEDNOV, ROBERT O. MESSING · 2001 to 2026
$9.5M
SYSTEMIC NEUROPHARMACOLOGYP50AA006420 · NIAAA · SCRIPPS RESEARCH INSTITUTE · PI SIGGINS, GEORGE ROBERT · 1985 to 2002
$5.1M
Neuroplasticity of the Extended Amygdala CRF circuitry in alcohol dependenceR01AA021491 · NIAAA · SCRIPPS RESEARCH INSTITUTE, THE · PI ROBERTO, MARISA · 2013 to 2024
$3.9M
Gene-environment interaction: the brain CRF system in alcohol preferring msP ratsR37AA017447 · NIAAA · SCRIPPS RESEARCH INSTITUTE, THE · PI ROBERTO, MARISA · 2016 to 2025
$3.7M
Neuroimmune mechanisms in stress and alcohol comorbidityR01AA027700 · NIAAA · SCRIPPS RESEARCH INSTITUTE, THE · PI ROBERTO, MARISA · 2019 to 2023
$2.4M
Synaptic Mechanisms underlying sex-differences in alcohol use disorderR01AA029841 · NIAAA · SCRIPPS RESEARCH INSTITUTE, THE · PI MARISA ROBERTO · 2022 to 2026
$2.0M
Gene-environment interaction: the brain CRF system in alcohol preferring msP ratsR01AA017447 · NIAAA · SCRIPPS RESEARCH INSTITUTE, THE · PI ROBERTO, MARISA · 2009 to 2013
$1.8M
Vasopressin Signaling in Pain and Alcohol DependenceR01AA025996 · NIAAA · LSU HEALTH SCIENCES CENTER · PI EDWARDS, SCOTT · 2018 to 2022
$1.7M
NIAAA NIH HHS K99 AA025408NIAAA NIH HHS P50 AA006420NIAAA NIH HHS P50 AA017823NIAAA NIH HHS P60 AA006420NIAAA NIH HHS R00 AA025408NIAAA NIH HHS R01 AA017447NIAAA NIH HHS R01 AA021491NIAAA NIH HHS R01 AA025996NIAAA NIH HHS R01 AA027700NIAAA NIH HHS R01 AA029841NIAAA NIH HHS R37 AA017447NIAAA NIH HHS T32 AA007456NIAAA NIH HHS U01 AA013498NIAAA NIH HHS U01 AA013520NIGMS NIH HHS K99 GM129454NIGMS NIH HHS R00 GM129454
6 · The paper itself

Abstract

Neuroimmune pathways regulate brain function to influence complex behavior and play a role in several neuropsychiatric diseases, including alcohol use disorder (AUD). In particular, the interleukin-1 (IL-1) system has emerged as a key regulator of the brain's response to ethanol (alcohol). Here we investigated the mechanisms underlying ethanol-induced neuroadaptation of IL-1β signaling at GABAergic synapses in the prelimbic region of the medial prefrontal cortex (mPFC), an area responsible for integrating contextual information to mediate conflicting motivational drives. We exposed C57BL/6J male mice to the chronic intermittent ethanol vapor-2 bottle choice paradigm (CIE-2BC) to induce ethanol dependence, and conducted ex vivo electrophysiology and molecular analyses. We found that the IL-1 system regulates basal mPFC function through its actions at inhibitory synapses on prelimbic layer 2/3 pyramidal neurons. IL-1β can selectively recruit either neuroprotective (PI3K/Akt) or pro-inflammatory (MyD88/p38 MAPK) mechanisms to produce opposing synaptic effects. In ethanol naïve conditions, there was a strong PI3K/Akt bias leading to a disinhibition of pyramidal neurons. Ethanol dependence produced opposite IL-1 effects - enhanced local inhibition via a switch in IL-1β signaling to the canonical pro-inflammatory MyD88 pathway. Ethanol dependence also increased cellular IL-1β in the mPFC, while decreasing expression of downstream effectors (Akt, p38 MAPK). Thus, IL-1β may represent a key neural substrate in ethanol-induced cortical dysfunction. As the IL-1 receptor antagonist (kineret) is already FDA-approved for other diseases, this work underscores the high therapeutic potential of IL-1 signaling/neuroimmune-based treatments for AUD.

Indexed as

AlcoholismEthanolAnimalsInterleukin-1betaMaleMiceMice, Inbred C57BLMyeloid Differentiation Factor 88p38 Mitogen-Activated Protein KinasesPhosphatidylinositol 3-KinasesPrefrontal CortexProto-Oncogene Proteins c-aktEthanolInterleukin-1betaMyeloid Differentiation Factor 88p38 Mitogen-Activated Protein KinasesPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktAktAlcoholIL-1R1IL-1βInterleukin 1MyD88Neuroimmunep38 MAPKPI3KsIPSCSynaptic transmission

Identifiers

PMID36863493
PMCPMC10106421

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.